HK Stock Market Move | TYK MEDICINES-B(02410) rose more than 5% in the morning session. The company is preparing a conditional listing NDA application for TY-9591.

TYK MEDICINES-B (02410) rose more than 5% in early trading, as of the time of writing, it rose by 3.73% to 13.35 Hong Kong dollars, with a turnover of 215.46 million Hong Kong dollars. On the news front, at the World Lung Cancer Congress in September of this year, the Edotinib tablet developed by BeiGene for the key phase II clinical trial of non-small cell lung cancer brain metastasis has attracted high attention from peers. It is reported that Edotinib tablet (TY-9591) is a highly selective small molecule inhibitor developed by BeiGene for EGFR classic mutations. The company has enrolled 224 patients who have completed the conditional approval for listing by November 2024 and submitted a pre-NDA application in April 2025, with the expectation of formally submitting the conditional listing application in the fourth quarter of 2025. The company stated at the mid-term performance meeting that it is currently preparing the conditional listing NDA application for TY-9591, for use in first-line treatment of lung cancer brain metastasis with epidermal growth factor receptor (EGFR) mutations, as well as conducting a Phase III clinical trial in China for TY-9591 monotherapy for use in first-line treatment of locally advanced (stage IIIb to stage IV) or metastatic NSCLC with EGFRL858R mutations.